Key facts
- Bexorg’s last known valuation is $160.0M (Sep 2025).
- It has raised $42.5M; the latest was Early Stage VC ($23.0M) in Sep 2025.
- Notable investors include Connecticut Innovations, Amplify Partners, Engine Ventures, E1 Ventures, Starbloom Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Bexorg
- ·The full record, as it builds
Funding rounds
No funding rounds for Bexorg are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bexorg
Developer of a whole-brain perfusion technology designed to support brain research and therapy development. The company offers a proprietary technology capable of maintaining and monitoring intact human brains, enabling researchers and drug developers to conduct detailed studies of neurological conditions.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2021
- Employees
- 30
- Website
- bexorg.com/
- Ownership
- Privately Held (backing)
Bexorg doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bexorg shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bexorg in its N-PORT filings yet. We sweep new filings monthly.